ESC 365 - Which patients will benefit most from FXI inhibition?

Open Access

Which patients will benefit most from FXI inhibition?

Session: How could factor eleven (FXI) inhibitors help your patients? New frontiers in thrombosis prevention

Topic: Atrial Fibrillation (AF)

Speaker: Professor V. Kunadian (Newcastle-Upon-Tyne, GB)

Sponsored by Bayer AG

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Vijay Kunadian

Newcastle University, Newcastle-Upon-Tyne (United Kingdom of Great Britain & Northern Ireland)

28 presentations

11 followers

3 more presentations in this session

Welcome and introduction.

Speaker: Doctor M. Patel (Durham, US)

What makes FXI inhibition different from current approaches to thrombosis prevention?

Speaker: Professor V. Caso (Perugia, IT)

Live Q&A.

Access the full session

How could factor eleven (FXI) inhibitors help your patients? New frontiers in thrombosis prevention

Speakers: Professor V. Kunadian, Doctor M. Patel, Professor V. Caso

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources